Rayner Intraocular Lenses Limited

Rayner Intraocular Lenses Limited specializes in the manufacturing of intraocular lenses (IOLs) for cataract surgery, providing innovative solutions that enhance surgical processes and improve patient care. Rayner Intraocular Lenses Limited, founded in 1910, is headquartered in the UK and focuses on developing advanced ophthalmic solutions. The company has undergone strategic pivots to enhance its product offerings and distribution capabilities. Tim Clover currently serves as CEO.

The company has engaged in 2 funding deals, with the most recent on June 28, 2021, when CVC Capital Partners acquired a majority stake from Phoenix Equity Partners, with the transaction expected to close in Q3 2021. Rayner Intraocular Lenses Limited offers a range of ophthalmic solutions, primarily focusing on intraocular lenses (IOLs) used in cataract surgeries. Their leading product, the RayOne IOL, incorporates patented Lock & Roll technology, facilitating dropless procedures with the use of OMIDRIA. The company serves healthcare professionals across North America, Europe, and other international markets, enhancing patient outcomes through innovative tools and a digital platform, RayPRO, which collects patient-reported outcomes over three years.

In 2023, Rayner Intraocular Lenses Limited reported a revenue of USD 81. 97 mn and an EBITDA of USD 27. 06 mn, generated through B2B transactions with healthcare professionals and surgical centers, focusing on the sale of their IOLs and OMIDRIA. Rayner Intraocular Lenses Limited aims to accelerate international expansion following the acquisition by CVC Capital Partners.

The company plans to introduce new products, including enhanced versions of existing IOLs, and aims to penetrate additional markets in Europe and Asia by 2023. The recent funding will support these initiatives, ensuring that resources are allocated towards expanding their product lines and market reach.